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Cytomegalovirus infection is associated with an increase in aortic stiffness in older men 
which may be mediated in part by CD4 memory T-cells 
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Human Cytomegalovirus (CMV) infection is associated with atherosclerosis, higher 
cardiovascular disease (CVD) risk, and an increase in memory T-cells (Tmem). T-cells have 
also been implicated in CVD, independently of CMV infection. To better understand the 
CMV-associated CVD risk, we examined the association between CMV (IgG) serostatus and 
central aortic (carotid-to-femoral) pulse wave velocity (cfPWV), an early, independent 
predictor of CVD. We also investigated if such an association might be reflected by the 
distribution of Tmem and/or other T-cell subsets. 
Methods: Healthy older volunteers (60-93 years) underwent routine clinical and laboratory 
evaluation, including assessment of cfPWV in eligible participants. Flow-cytometry was used 
to assess proportions of memory T-cells, CD28null T-cells, and CMV-specific T-cells. The 
following associations were examined; CMV serostatus/cfPWV, CMV serostatus/proportion 
of Tmem, proportion of Tmem/cfPWV, CD28null T-cells/PWV, and CMV-specific T-
cells/cfPWV. Linear regression models were used to adjust for age, sex, socioeconomic 
status, smoking, waist-to-hip ratio, cholesterol, and blood pressure as required.  
Results: Statistically significant positive associations were found (P-values for the fully 
adjusted models are given); CMV serostatus/cfPWV in men (P ≤ 0.01) but not in women, 
CMV serostatus/proportions of CD4 Tmem in men (P ≤ 0.05) but not in women; proportions pf 
CD4 Tmem/cfPWV among CMV seropositive (CMV+) people (P<=0.05) but not CMV 
seronegative (CMV-) people.  
Conclusion: CMV infection increases the CVD risk of older men by increasing cfPWV. This 
may be mediated in part by increased proportions of CD4 Tmem, higher numbers of which are 
found in CMV+ older people and more so among men than women. Given the high 
prevalence of CMV worldwide, our findings point to a significant global health issue. Novel 
strategies to mitigate the increased CVD risk associated with CMV may be required.  
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A CMV-associated increase in central aortic stiffness in older men but not women might be 
explained by a bigger CMV-induced increase in pro-inflammatory/proatherosclerotic CD4 






























A recent meta-analysis of 10 studies across a total of 34,564 participants concluded 
that human Cytomegalovirus (CMV) infection (i.e., the status of being anti-CMV IgG 
seropositive, or ‘CMV+’) increases the overall risk of cardiovascular disease (CVD) by 22% 
[1]. However, the mechanisms underlying this association are not well understood. As CMV 
prevalence increases with age, the effects of CMV infection and aging are difficult to 
dissociate. CMV is often considered a confounder with respect to age-associated pathologies 
and vice versa. CMV infection has been directly associated with precursors to cardiovascular 
disease such as hypertension and atherosclerotic changes in a number of human and animal 
studies [2-4]. For example, a mouse model of murine CMV (MCMV) infection demonstrated 
that, apart from causing an increase in blood pressure, MCMV was independently a co-factor 
for aortic intimal thickening [3]. In humans, being CMV+ has also been found to be 
associated with increased blood pressure [4].  
The exact mechanisms by which CMV infection contributes to CVD remain unclear, 
but there is increasing evidence that some of the major effects of CMV on the cardiovascular 
system are mediated by its impact on certain immune cell subsets, particularly antigen-
experienced, memory-T-cells (Tmem) [5-7]. T-cells in general, and particularly CD4 T-cells, 
have been shown to be associated with atherosclerosis and atherothrombosis [8]. Infection 
with CMV induces high frequencies of pro-inflammatory, CMV protein-specific effector T-
cells [9, 10], but also increases the proportions of antigen-experienced CD4 and CD8 T-cells 
in general [9-11]. Since vascular endothelial cells are a primary target tissue for CMV 
infection [12], CMV-specific T-cells may be targeted to vascular endothelium causing local 
damage; however, upregulated adhesion molecules on damaged endothelium may also attract 
non-CMV-specific T-cells [13, 14]. A study in rats showed that intraperitoneal CMV 
infection, administered immediately after experimental vascular injury, significantly 
increased the neointimal response to that injury (i.e., intima to media ratio). Interestingly, this 
effect was independent of the presence of virus in the injured epithelium itself, suggesting 
that CMV-driven pro-inflammatory T-cells may non-specifically infiltrate injured vasculature 
[15].  
Men and women differ with regards to age and CMV-associated changes to the 
immune system [6, 16], which may help explain sex differences in mortality from coronary 
heart disease and stroke [17]. For example, in older men CMV infection induces larger 
proportions of highly differentiated CD4 and CD8 effector memory T-cells than in older 
women [6]. Such effector cells may have a destabilizing effect on atherosclerotic plaques [8]. 
Older women, by contrast, have more regulatory T-cells than older men, which have a 
stabilizing effect on atheromatous lesions [8]. This might explain why atherosclerotic plaques 
are more stable in older women [18]. 
Compliance of the large elastic arteries is a well-established, early, and sensitive 
marker of cardiovascular risk, which can be measured non-invasively as central aortic pulse-
wave velocity [19]. It is calculated from the path length travelled by the pulse wave in the 
carotid-to-femoral region and its transit time, and referred to as carotid-to-femoral pulse-
wave velocity (cfPWV). cfPWV has a well-documented positive correlation with 
cardiovascular outcomes such as heart attacks and stroke, independently of traditional risk 
factors [20, 21].  
It was recently shown that CMV infection is associated with increased cfPWV in 
chronic kidney disease (CKD) [22], the latter affecting 11-13% of people worldwide [23]. 
Since the prevalence of CMV infection (i.e. positive IgG serology) is about 80% in over 65 
year-olds in European studies [24, 25] and even higher elsewhere [26, 27], any detrimental 
effect of CMV on cardiovascular health should be of major concern. Being able to 
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demonstrate a similar effect of CMV infection on cfPWV in generally healthy older people 
would significantly corroborate the role of CMV as a driver of CVD and underscore its 
relevance to global health [20, 21]. In the present work we examine if an association between 
CMV serostatus and cfPWV indeed exists in generally healthy older people. Also, in light of 
the suspected role of T-cells in the pathogenesis of atherosclerosis and cardiovascular disease 
[7, 8] and CMV’s role in driving memory T-cell expansion [5, 6], we examine the 
distribution of different antigen-experienced T-cell subsets (Tmem) as well as the size of the 
CMV-specific T-cell response across our population of older CMV+ and CMV- men and 
women. This allows us to examine the effect of T-cells on cfPWV that may be mediated by 




In older men but not women, CMV-infection is associated with increased cfPWV 
A possible association of CMV infection with an increase in cfPWV (as an indicator 
of CVD risk) was the primary focus of our study. Across our total cohort of older people (60-
93 years) cfPWV (median) was within the reported normal range [28] with 8.9 m/s (IQR: 2.4 
m/s) among 60-70 year-olds (N = 91), 9.8 m/s (IQR: 3.4 m/s) in 70-80 year-olds (N = 29), 
and 12.2 m/s (IQR: 3.3 ms) in 80-90 year-olds (N = 15). The prevalence of CMV infection 
was 54% among those assessed in the vascular lab (a study flow-chart is provided in Figure 
S1). 
In CMV+ men the median cfPWV was 1.1 m/s higher than in CMV- men (P = 0.022). 
Among women, the difference was in the opposite direction but not statistically significant 
(Table 1 and Figure S2). According to published normal ranges, a difference of 1 m/s roughly 
corresponds to an age difference of about 5-10 years in the investigated age group [28]. In 
order to confirm this important finding, we built linear regression models examining the 
association between CMV infection (positive IgG-serology) and cfPVW (Table 2) while 
adjusting for relevant covariates. In the entire cohort of N = 136 individuals (men and 
women) we observed no statistically significant association between CMV serostatus and 
cfPWV, neither in the crude nor adjusted models. However, since we had observed a 
significant difference in cfPWV between CMV+ and CMV- older men but not women, we 
added the interaction term ‘CMV serostatus*sex’ to the model. This term was significant at 
all levels of adjustment with P = 0.026 in the fully adjusted model, indicating that sex indeed 
influenced the effect of CMV-seropositivity. We subsequently stratified the model by sex. In 
the stratified but unadjusted model the mean cfPWV was 0.046 log10-units higher for CMV+ 
versus CMV- men (95% CI 0.001, 0.092; P = 0.046). In agreement with the observed median 
difference between these groups this translates into a difference of cfPWV of approximately 
1.11 m/s (95% CI: 1.00 m/s to 1.24 m/s). The effect of CMV was slightly increased after 
adjusting for the demographic factors, age and socioeconomic standing (SES) (P = 0.016), 
and even stronger after additionally adjusting for smoking pack-years and waist-to-hip ratio 
(WHR). After further adjustment for lying systolic blood pressure (SBP) and the ratio of total 
cholesterol over HDL-cholesterol (TC/HDL-C), cfPWV was 0.059 log10-units higher in 
CMV+ compared to CMV- men (95% CI: 0.024, 0.093; P = 0.001) translating into a 
difference of cfPWV of about 1.13 m/s (95% CI: 1.06 m/s to 1.24 m/s). In contrast to this, a 
negative but not statistically significant association was observed among women. Cohort 
characteristics relevant to the linear regression models are shown in Table 1. The complete, 
fully adjusted model is shown in the supplementary data (Table S1). There were no 
significant differences between CMV+ and CMV- individuals with regard to blood pressure 
control (Table 1 and Table S2) or blood pressure medications (Table S3) neither in the entire 
cohort nor among men or women separately. As would be expected in this case, adjusting for 
the use of blood pressure medications made no tangible difference to the fully adjusted 
regression models (Table S4).  
 
It is well known that CMV infection skews T-cell subset distribution towards an advanced 
memory phenotype and it has been reported that this happens more so in older men than in 
older women [6, 16]. Therefore, and because of the role of T-cells in cardiovascular disease it 
seemed pertinent to explore if the distribution of T-cell in terms of naïve and memory subsets 




The proportions of memory T-cell subsets differ between CMV+ and CMV- individuals in 
both men and women 
Whole blood T-cell phenotyping data was available for a sub-cohort of N = 123 
individuals who also had valid cfPWV measurements. Characteristics of this sub-cohort are 
reported in supplementary Table S5 (parameters used in linear regression models), Table S6 
(additional information on blood pressure and smoking), and Table S7 (medications). In this 
sub-cohort, the association of CMV serostatus with cfPWV in men shown in Table 2 
remained significant at all levels of adjustment. We used the surface markers C-C chemokine 
receptor 7 (CCR7) and CD45RA to identify naïve T-cells (CCR7+CD45RA+, TNA), as well 
as central memory (CCR7+CD45RA-, TCM), effector memory (CCR7-CD45RA-, TEM), and 
revertant memory T-cell subsets (CCR7-CD45RA+, TEMRA), collectively referred to as Tmem 
(Figure S3) [29]. 
We examined CD4 and CD8 T-cell subset differences (i.e., relative population size) 
between CMV+ and CMV- individuals in the entire cohort but also separately among male 
and female participants, because CMV serostatus was associated with a difference in cfPWV 
in men but not women (Figure 1).  
When comparing CMV+ to CMV- individuals, significant subset differences were 
found with regards to CD4 TNA and CD4 TEMRA (Figure 1A, top) and all CD8 subsets (Figure 
1B, top). Upon stratification by sex these differences seemed to be stronger among men than 
women (relative difference of median subset size, only significant differences are listed). In 
CMV+ compared to CMV- men, CD4 TNA were 30.5% lower (P = 0.004), and CD4 TEMRA 
63.3% higher (P = 0.005) (Figure 1A, middle), CD8 TNA, TCM, and TEM were 71.1% (P = 
0.000), 51.2% (P = 0.000), and 19.4% (P = 0.015) lower, respectively, however, CD8 TEMRA 
cells 77.8% higher (P = 0.000) (Figure 1B, middle). In CMV+ compared to CMV- women, 
CD4 TEMRA cells were 40.1% higher (P = 0.003) (Figure 1A, bottom), CD8 TNA were 39.5% 
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Figure 1. Differential distribution of canonical memory T-cell subsets in different sub-
groups defined by CMV serostatus and sex. A. Box plots show the distribution of CD4 
TNA, TCM, TEM, and TEMRA subsets in CMV- and CMV+ individuals among the entire cohort 
(top), men (middle) and women (bottom). B. Box plots show the distribution of the 
corresponding CD8 T cell subsets in each group. Box plots show median and interquartile 
range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and extreme values 
(*). Significant differences are indicated by P-values. 
 
Statistically significant differences between men and women regarding Tmem subset 
distribution were observed in the entire cohort and among CMV+ individuals but not CMV- 
individuals (Figure S4). In CMV+ men CD4 TNA were 28.4% lower (P = 0.002) and CD8 
TNA 66.1% (P = 0.001) lower than in CMV+ women (relative difference of median subset 
size).  
 
The overall effect of CMV infection on the canonical memory T-cell subsets appeared 
to be well captured by either the size of the naïve subset (TNA) or the Tmem subset (TCM, TEM, 
and TEMRA). Since TNA and Tmem subset sizes are reciprocal, only the size of the Tmem subset 
was used for further analysis. Figure 2 summarizes the differences in CD4 and CD8 Tmem 






Figure 2. The percentage of antigen-experienced CD4 Tmem cells is higher in CMV+ 
than CMV- individuals among men but not women. A. Box plots show the proportions of 






























































plots show the proportions of CD4 and CD8 Tmem in the entire cohort (top), CMV- 
individuals (middle), and CMV+ individuals (bottom). Box plots show median and 
interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and 
extreme values (*). Significant differences are indicated by P-values. 
 
In the entire sub-cohort CD4 Tmem were 15.7 % higher (P = 0.021) in CMV+ 
compared to CMV- individuals (relative median differences given) (Figure 2A, top). Among 
men the corresponding difference was 31.6% (P = 0.004) (Figure 2A middle), but among 
women only 1.9% (n.s.) (Figure 2A bottom), indicating a much stronger effect of CMV in 
men than in women. In the entire cohort CD8 Tmem were 12.2% higher (P = 0.000) in CMV+ 
compared to CMV- individuals (Figure 2A, top) but the corresponding difference among men 
and women was very similar (12.0%, P = 0.000 and 10.4%, P = 0.013, respectively) (Figure 
2A, middle and bottom).  
When directly comparing the sexes among CMV+ people, the CD4 Tmem subset was 
27.9% bigger (relative median difference) in men than in women (P = 0.002, Figure 2B, 
bottom), however, the CD8 Tmem population was only 9% larger in men than in women (P = 
0.001).  
 
We wondered therefore if the significant difference in CD4 Tmem between CMV+ and 
CMV- men (which was not found in women) might explain the association between CMV 
serostatus and pulse wave velocity that we had observed in men (but not in women). In order 
to be sure that the difference in CD4 Tmem was truly associated with CMV serostatus and not, 
for example age, we first tested the effect of potential confounders in a linear regression 
model (Table 3). The model was initially run on the entire sub-cohort and was adjusted for 
age, sex, SES, smoking, and WHR, but not for SBP and cholesterol, as these last two 
covariates have no known relationship with Tmem subset distribution. To account for the 
observed sex differences revealed by our memory T-cell subset analysis, the model was 
subsequently stratified by sex, which confirmed a significant effect of CMV on CD4 Tmem in 
men but not women We also tested the effect of CMV serostatus on CD8 Tmem, which, as 
expected, was similar in both sexes and significant at all levels of adjustment (Table S8).  
 
Antigen-experienced CD4 T-cells correlate positively with cfPWV in CMV+ but correlate 
negatively in CMV- older people 
We next assessed whether the proportions of CD4 Tmem were associated with cfPWV. 
Bivariate correlation analysis indicated that among CMV+ individuals CD4 Tmem population 
size was moderately positively associated with cfPWV, but not in the whole cohort. Among 
CMV- individuals CD4 Tmem population size was moderately negatively associated with 
cfPWV (Figure 3A). No significant correlation between the proportions of CD8 Tmem and 
cfPWV was identified in the entire cohort or after stratification by CMV-status (Figure 3B). 
As expected in this cohort of over 60 year-olds, no significant changes in CD4 Tmem or CD8 





Figure 3. The percentage of antigen-experienced CD4 Tmem-cells correlates positively 
with cfPWV in CMV+ but correlates negatively in CMV- people. Scatterplots show the 
relationships between the percentage of antigen-experienced CD4 Tmem-cells (A), or CD8 T-
cells (B) and cfPWV. The entire cohort is shown on the left, CMV+ individuals in the 
middle, and CMV- individuals on the right. cfPWV was Log10-transformed to improve 
visualization. Regression lines denote the results of regression on Tmem. The Pearson 
correlation coefficient (R) is shown with each regression line. 
 
The association between CD4 Tmem and cfPWV was confirmed in a linear regression 
model (Table 4). The model was run in the entire sub-cohort as well as after stratification by 
CMV status based on the differences observed between CMV+ and CMV- people. 
Adjustment for covariates in this model was analogous to the first model testing the effect of 
CMV on cfPWV. As expected, in the whole cohort, no significant effect of CD4 Tmem on 
cfPWV was identified, neither crude nor after adjustment for CMV or at any further level of 
adjustment (models 2-5). Splitting the model by CMV serostatus (in analogy to Figure 3) 
identified a statistically significant positive association between CD4 Tmem and cfPWV 
among CMV+ people but a significant negative association among CMV- people. However, 
following adjustment, the positive association among those who were CMV+ remained 
significant but the beta regression coefficient was somewhat reduced from 0.249 (unadjusted) 
to 0.181 (fully adjusted). Since both cfPWV and Tmem were log transformed for inclusion in 
the model, the beta coefficients in Table 4 are given in log units as well. A beta of 0.181 for 
CMV+ people (fully adjusted model) translates into an approximate increase of 0.3 m/s of 
cfPWV for every 10% increase of CD4 Tmem. This clearly is a sizeable effect (Compare 
Figure 3, which corresponds to the unadjusted model). The negative association between 
CD4 Tmem and cfPWV among CMV- individuals lost significance following adjustment. In 
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least partially accounted for by the difference in size of the CD4 and CD8 Tmem populations 
between men and women. 
 
 
CD28null T-cell subset size is not significantly associated with cfPWV 
As a T-cell subset of particular interest, CD28null T-cells are implicated in vascular 
damage and particularly in destabilizing atherosclerotic plaques [30]. CD4 CD28null T-cells 
are strongly associated with CMV infection, with many actually being CMV-specific and 
occurring only in small frequencies in CMV- individuals [31]. CD28null T-cells were gated as 
CD3+/CD8+ or CD4+/CD28null/CD27- [31]. While no significant correlation was observed 
between CD28null T-cells and Tmem among CMV- individuals (CD28null CD4 T-cell 
proportions were very low among CMV- people), the correlation was moderate among 
CMV+ individuals (Figure 4A). However, there was no significant correlation between CD4 
or CD8 CD28null T-cells and cfPWV, neither among CMV- nor among CMV+ individuals 
(Figure 4B). Because no meaningful association between CD28null T-cells and cfPWV was 





Figure 4: The proportions of CD4 and CD8 CD28null T-cells show a moderate 
correlation with Tmem among CMV+ people but do not correlate with cfPWV. CD28null 
T-cells were measured by flow-cytometry (gated as CD28null/CD27- T-cells). A. Correlations 
between CD28null CD4 (top) and CD8 (bottom) T-cells and Tmem are shown separately for 
CMV+ and CMV- people. B. Correlations between CD28null CD4 (top) and CD8 (bottom) T-
cells and cfPWV. Regression lines denote the results of regression on Tmem or CD28null T-















































































CMV-specific T-cells are not directly associated with cfPWV 
We also examined if the number of CMV- specific CD4 or CD8 T-cells were 
associated with cfPWV (the analysis being obviously limited to CMV+ individuals). These 
cells are known to predominantly have an advanced memory phenotype [32]. We measured 
activated CMV-specific CD4 and CD8 T-cells following stimulation of fresh PBMC with 
CMV protein-spanning peptide pools [33, 34]. The proteins for stimulation were selected 
from a panel of 19 proteins that had been found to be representative of all CMV T-cell target 
antigens in a mixed ethnicity population [35]. However, 3 proteins against which we had not 
detected a single response in White British people in a recent study were left out [9, 10]. The 
remaining 16 proteins were arranged in 14 stimulation pools (Table 5). Intracellular 
Interleukin-2 (IL-2), Tumor-necrosis factor (TNF), and Interferon-gamma (IFN-g) were used 
separately or in combination to identify activated cells and the sum of the responses to all 
pools was used as a compound measure of T-cell responsiveness [35]. This avoids the 
significant bias introduced by measuring responses to single proteins [36]. Complete 
measurements were available for 69 CMV+ individuals who also had valid cfPWV 
measurements (33 male and 36 female). Figure S5 shows the distribution of CD4 and CD8 T-
cell responsiveness (i.e., presence or absence of a response) across the tested peptide pools in 
our study.  
Bivariate correlation analysis did not identify significant associations between the 
percentages of CMV-specific CD4 or CD8 T-cells and cfPWV (Figure 5A and B) for any of 
the individual stimulation pools (not shown). No further analyses were carried out to test 




Figure 5: The frequencies of CMV-specific CD4 and CD8 T-cells do not correlate with 
cfPWV. Responses were measured by intracellular cytokine staining following stimulation of 
CMV-specific CD8 T-cells, any cytokine (%)
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fresh PBMC with 16 CMV protein-spanning peptide pools arranged in 14 stimulation pools. 
For each protein the percentage of cells expressing each activation marker (IL-2, TNF, or 
IFN-g) or at least one of them was determined. The summated responses across all 14 CMV-
peptide stimulation pools are plotted against cfPWV. Response size was determined based on 
the presence of at least one activation marker (A) or (the usually dominant) IFN-g only (B). 
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Materials and methods 
 
Ethics Statement 
The study was approved by the UK National Research Ethics Service (NRES) ‘London Centre’ 
(Reference 13/LO/1270). Written informed consent was obtained from all participants. The 
study was conducted in accordance with the Declaration of Helsinki. 
 
Participants and samples 
Participants were recruited through general practices (GP) in Southern England with help of 
the primary care research network (PCRN). Inclusion criteria were; White British ethnicity 
and age 60 years or older; exclusion criteria were; known immunodeficiency (including HIV 
infection), organ transplantation, use of immunosuppressive or immune-modulating drugs 
within the last year (excluding acetylsalicylic acid ≤ 100 mg/day), cancer or treatment for 
cancer within the previous 5 years, insulin dependent diabetes, moderate or advanced renal 
failure, liver disease, endocrine disorders (except corrected thyroid dysfunction), manifest 
autoimmune disease, dementia/mental incompetence, known alcoholism or other drug abuse, 
acute infection or illness in the last 4 weeks, raised body temperature (> 37.5 °C), moderate 
or severe heart failure (NYHA III or IV), inability to lie flat. Individuals with typical, age-
related cardiovascular morbidity were not excluded. A flow-chart outlining recruitment and 
response data is shown in Figure S1. Further details are available in the online supplement.  
 
Participant data and sample collection 
Information collected at the main appointment included demographic and lifestyle factors 
including a detailed smoking history and socioeconomic status (SES), prior medical history, 
and medications. All participants also underwent a physical examination. Additional 
measurements included height, weight, waist and hip circumference, body composition, 
blood pressure, and vascular stiffness. Blood samples were taken by peripheral venepuncture. 
 
CMV Serology 
CMV immunoglobulin G (IgG) serology (Architect CMV IgG, Abbot, Maidenhead, UK) was 
performed at the Brighton and Sussex University Hospital Trust (BSUHT) virology laboratory 
using the same routine assay as used for all hospital patients. Individuals whose serum samples 




A detailed medical history included all current medications. An overview of common 
medications is provided for the entire cohort (Table S3) and separately for the sub-cohort 




A detailed smoking history was collected which accounted for all types of tobacco smoking. 
Smoking other than cigarettes was translated into cigarette equivalents as follows; large 
cigars (4), small cigars/cigarillos (2), self-rolled cigarettes (1), pipes per bowl (1.5) [37]. The 
smoking history was represented by (cigarette) pack-years. Separate periods of smoking 
interrupted by periods of non-smoking were summed to determine the total number of years 
that an individual had smoked in their lifetime. Additional information on smoking is 
provided in Table 1 and Table S2 for the entire cohort as well as Table S5 and Table S6 for 




Participants were asked to report their last job title and a description. We used the UK 
National Statistics Socio-economic Classification 2010 [38] to generate job title codes. The 
ONS NS-SEC online coding tool [39] was then used to assign ‘analytic categories’ and 
‘operational categories’ for each participant based on the job title code. This tool utilises the 
job title code and takes into account whether a person is self-employed or unemployed and if 
they have any supervisory roles. Ambiguous cases were assigned the highest of any possible 
codes. We used the operational category to represent SES in our analysis.  
 
PWV 
Assessment of carotid-to-femoral PWV (measured in m/s) was carried out using the 
Complior® system (Alam Medical, Paris, France) at room temperature with the patient 
supine and after 10 minutes of resting. Patients had been asked to refrain from smoking, 
eating or drinking caffeinated drinks for 3 hours and drinking alcohol for 10 hours before 
measurements. Please find additional details in the online supplement. 
 
Resting blood pressure  
Resting blood pressure was measured in duplicate using standardised BP monitors 
(OMRON705-IT, Omron Electronics Ltd., Milton-Keynes, UK). 
 
Laboratory evaluation of blood samples 
Participant samples were treated like routine clinical samples and sent to the BSUHT 
pathology laboratory immediately after venepuncture. Analysis included routine full blood 
counts and fasting lipid profiles (total cholesterol, HDL cholesterol, triglyceride, TC/HDL 
ratio, non-HDL cholesterol). 
 
Whole blood T-cell phenotyping 
Fresh whole blood was stained with fluorescence-labelled monoclonal antibodies: CD45, CD3, 




Overlapping peptide pools representing 16 CMV different proteins arranged in 14 pools were 
used in T-cell stimulation assays (for details see online supplement).  
 
CMV reactivity of T-cells 
Freshly obtained PBMCs from CMV+ individuals were stimulated overnight (16 h) with 
overlapping CMV protein spanning peptide pools and subsequently stained and acquired by 
flow-cytometry. Surface markers included CD3, CD4, CD8, CD45RA, CCR7. Intracellular 
markers included IL-2, TNF, and IFN-g (activation markers). The gating strategy is shown in 
Figure S6. Based on the positive control stimulation (SEB) a ‘response region’ was defined in 
a given plot (e.g., CD4 versus IFN- g) in which cytokine positive events (IFN- g in the example) 
were located. A positive cytokine response following stimulation with peptide pools was then 
identified in an analogous plot as a clustered population of activated cells displaying the 
activation marker in question (i.e. IFN- g in the example) provided that (i) the clustered 
population of activated events occurred in the response region, and (ii) the cluster of activated 
cells comprised at least 0.01% of the reference population (CD4 or CD8 T-cells) after 
subtracting the corresponding percentage of cytokine positive events found in the same region 




Statistical analysis was carried out using the SPSS 25 software package (IBM, London, UK). 
Our entire analytic sample (cohort) of N = 136 participants contained only individuals with 
valid cfPWV measurements who also had complete medical histories/data for all parameters 
of interest (hip and waist circumference, pack-year smoking history; socioeconomic status, 
pulse pressure, total and HDL cholesterol). Whole blood T-cell phenotyping was further 
available for a sub-cohort of N = 123 individuals. Non-parametric tests (Mann-Whitney U 
Test) were used to compare cfPWV and T-cell subset sizes between groups of individuals. 
Linear regression models were built to examine the association between CMV serostatus and 
PWV. For use in such models a number of parameters were log-transformed to improve 
normality, e.g., cfPWV and systolic blood pressure. Additional details of the statistical 





Our main aim was to investigate whether CMV infection (i.e., positive IgG serostatus) 
is associated with increased central aortic stiffness in generally healthy people over 60 years 
of age. Importantly, we identified a positive association of CMV serostatus with increased 
cfPWV among men indicating an increase in CVD risk [19, 28]. Because of the known 
associations of (i) CMV infection with Tmem expansions [32] and (ii) Tmem subsets with 
atherosclerosis [7, 8] we examined if Tmem subset size and distribution in our cohort differed 
between CMV+ and CMV- individuals among men and women and might be associated with 
the difference in cfPWV that we had observed between CMV+ and CMV- men. Indeed, 
significant differences in CD4 Tmem distribution between CMV+ and CMV- individuals were 
only found among men, which raised the question of whether CD4 Tmem cells are associated 
with increased cfPWV and so could help explain the differential effect of CMV on cfPWV in 
men and women. 
Whereas in the whole cohort no correlation between CD4 or CD8 Tmem subset size 
and cfPWV was identified, a positive correlation between CD4 Tmem and cfPWV was seen 
among CMV+ people but a negative correlation between these parameters was found in 
CMV- people. Linear regression confirmed a significant positive association between CD4 
Tmem population size and cfPWV in CMV+ individuals at all levels of adjustment, however, 
the negative association between the same parameters among CMV- individuals was lost. 
Meanwhile, regarding CD8 Tmem population size there was still no significant association 
with cfPWV after stratifying by CMV serostatus.  
Prompted by published work [40, 41] and the known, close link between CMV 
infection and the proportions of CD28null T-cells [30, 31] we also examined correlations 
between CD28null T-cell population size and cfPWV. We were, however, unable to confirm a 
significant effect of CD28null CD4 or CD8 T-cells on cfPWV. Since a CMV-associated effect 
of T-cells on cfPWV could also be mediated by CMV-specific T-cells, we additionally tested 
associations between CMV-specific CD4 or CD8 T-cells and cfPWV but no significant 
association was elucidated either.  
Our results therefore show that (i) CMV infection is associated with statistically 
significant increases in cfPWV and CD4 Tmem in older men but not women, (ii) that CMV is 
linked to larger increases in CD4 Tmem in men than in women, and (iii) that the proportions of 
CD4 Tmem have a moderate but statistically significant positive association with cfPWV 
among CMV+ individuals. This raises the possibility that the effect of CMV infection on 
cfPWV is at least partly mediated by CD4 Tmem and observable in men but not women 
because upon CMV infection CD4 Tmem do not increase to the same extent in women as in 
men. 
To our knowledge, sex as a possible modifier of the association of CMV with 
increased CVD risk has never been reported nor specifically investigated. For example, a 
very recent analysis of five longitudinal older cohorts concluded that CMV infection is not 
associated with all-cause or cardiovascular mortality in community-dwelling older adults 
[42]. However, authors did not consider the possibility of differential effects of CMV in men 
and women, different proportions of CMV+ individuals among men and women, or 
differences in cardiovascular disease burden in those dying from other causes. Had we not 
considered differential effects of CMV in men and women in our study, we would not have 
detected an effect of CMV on cfPWV as it seemed to work in opposite directions in the two 
sexes. Interestingly, the BELFRAIL study of over 80 year-olds in Belgium [43] suggested 
that being CMV+ might have a protective effect in older women with regards to all-cause 
mortality at 3.3 years. The mechanism behind this effect has so far remained unclear but its 
presence appears to confirm an important difference in how male and female immune 
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systems handle this virus. Identifying and understanding sex-specific pathology therefore is 
extremely important in order to allow proper tailoring of preventative and therapeutic 
strategies according to sex. There are many examples of sex differences with regards to 
disease susceptibility and outcomes in particular in the field of autoimmunity and 
inflammation [44]. Immune system differences between the biological sexes are plentiful and 
may be mediated by sex hormones, however, often persist beyond the menopause [45-47]. 
Data from mouse models have confirmed sex differences in the way CMV affects the 
immune system by showing that male mice produce more inflammation in response to 
murine CMV (MCMV) infection than female mice. This seems to be related to higher 
expression of Toll-Like-Receptor 9 (TLR9) in males [48]. Higher expression of TLR9 results 
in a stronger innate and adaptive immune response against MCMV, which drives advanced 
T-cell differentiation. If the same is true in humans, men will produce more inflammation in 
response to CMV infection than women, contributing to increased numbers of memory T-
cells and increased vascular damage in later life. 
With regard to vascular damage in the context of CMV infection it is important to 
consider that EC are a primary target tissue of CMV infection. CMV-specific CD4 memory 
T-cells can damage and infiltrate infected endothelium because they display a highly 
differentiated memory phenotype with increased secretion of pro-inflammatory cytokines 
[13, 14]. Changes induced by endothelial inflammation include the upregulation of adhesion 
molecules, which, importantly, will also allow non-CMV-specific CD4 T-cells to infiltrate 
these areas, since adhesion molecules do not discriminate between T-cells of different 
antigen-specificity. In that sense, CMV-infection/CMV-specific T-cells may act as enablers 
allowing large numbers of activated memory/effector T-cells with a wide spectrum of 
antigen-specificities to infiltrate the vasculature [49]. By virtue of unspecific by-stander 
activation these might contribute to vascular inflammation, sclerosis and, ultimately reduced 
elasticity. This could explain the observed positive association of CD4 Tmem with increased 
cfPWV in CMV+ people observed in our study. 
The CD28null subset of Tmem has attracted particular interest in the field of 
atherosclerosis, in particular coronary artery disease [30, 31]. However, we were unable to 
identify an association between CD28null T-cells and cfPWV despite the fact that an 
association of CD4 CD28null T-cells with cfPWV was previously reported in patients with 
ANCA-associated vasculitis (AAV) [41]. It is possible that the presence of autoimmune 
disease is an important amplifier of this association [50].  
Regarding the role of CMV-specific T-cells, the CMV-specific portion of the entire 
T-cell repertoire as such is very difficult to quantify. It would essentially require testing 
responses against all potential CMV T-cell targets [35]. Using the summed response to a 
range of peptide pools representing the most frequently recognized CMV-proteins (as in the 
present study) is far better than focusing on single or just a few proteins [35, 36], however, 
still does not mean that CMV-specific T-cell immunity was captured in a representative way. 
This could be one reason why the size of the CMV-specific T-cell response was not 
associated with cfPWV in our study. However, given that not even a weak association was 
found a more plausible explanation might be that, as discussed above, CMV infection and 
CMV-specific T-cells only initiate the process of vascular infiltration by other 
effector/memory T-cells but that CMV-specific T-cells do not themselves cause most of the 
damage. Interestingly, others have reported a positive correlation between the proportions of 
CD8 T-cells recognizing the CMV UL83 protein and PWV in a cohort of N = 123 CMV+ 
Korean individuals (including patients with hypertension, coronary artery disease, diabetes 
mellitus, and healthy subjects), however, this association was much weaker still than the one 
we found between CD4 Tmem and cfPWV [40]. Based on the available data it would appear 
therefore that the direct contribution of CMV-specific T-cells to vascular stiffness is small.  
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Our study may be limited somewhat by a low participant response rate to the 
invitation which could affect the generalizability of our results to a degree. The reasons for 
this low rate of response potentially included the need to be fasting on arrival, the advised 
duration of the appointment of several hours, and the necessary travel to the investigation 
unit. These requirements might have biased the study in such a way that fitter individuals 
were more likely to self-select for participation. The fact that (i) we instructed GP practices to 
recruit generally healthy individuals and (ii) CMV status was unknown largely avoided any 
referral bias with respect to the presence of CMV-associated pathology or vascular changes. 
However, since in older people CMV infection has been associated with frailty [51] and 
chronic conditions for which individuals were excluded (such as insulin-dependent diabetes) 
[52], CMV+ individuals, in particular, might have been less likely to participate. However, 
such an effect would probably have biased the results against the detected association 
because frailty is itself associated with higher aortic pulse wave velocity [53] and so is 
diabetes at older ages [54]. The percentage of CMV seropositive individuals in the study 
(54%) was marginally below but very close to the published CMV prevalence in the UK 
among 40-79 year-olds (59%) [55] and cfPWV measured in our study matched published 
normal values very closely [28]. The slightly lower than expected seroprevalence was in line 
with our previous study in healthy older people in the same region of the UK [10] and, given 
that CMV infection is associated with a range of morbidities, especially at older ages [4, 51, 
52], was probably the result of selecting older participants that were generally fit and well. 
It was part of the study design to include only White British people in order to avoid 
differences in genetic background between CMV+ and CMV- participants affecting the 
results. This is a limitation with regards to generalizing our results to other ethnic groups and 
future confirmatory studies should include people of diverse biogeographical ancestry, 




In conclusion, an association of CMV infection with increased central aortic PWV in 
generally healthy, White British older males is an alarming finding. If this association 
extends to healthy older men in general it would represent a significant global health issue, 
given that CMV prevalence is as high or higher than 90% in large parts of the world [26]. In 
order to address this problem, specific preventative strategies may be needed to mitigate the 
additional CVD risk of CMV+ males. This might involve strategies to prevent CMV-driven 
CD4 Tmem expansion, for example. It was previously shown in mice that treatment with 
Valaciclovir can reverse MCMV-specific CD8 T-cell expansion [56]. Whether a similar 
approach would work for CD4 T-cells and in humans has yet to be established. Another 
potentially interesting agent could be Rapamycin, a safe and widely used immuno-
modulatory drug that was recently shown to have anti-aging properties, enhance immune 
function and reduce infections and inflammation in older people [57, 58] but also to possess 
anti-CMV activity [59]. In order to be able to develop the best therapeutic strategies in future, 
it is paramount that awareness of the health risks associated with chronic CMV infection 
increases among scientists and physicians. Further studies should be conducted to confirm 
our findings and identify the most suitable therapeutic targets in this complex interplay of 
CMV infection and the (aging) immune system.  
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Abbreviations: cfPWV: carotid-to-femoral pulse wave velocity, CMV: cytomegalovirus; 
CVD: cardiovascular disease; IQR: Interquartile range, SES: socioeconomic status, TC/HDL-
C: ratio of total cholesterol over high-density lipoprotein (HDL) cholesterol, Tmem: memory T 
cells, WHR: waist-to-hip ratio 
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Table 1. Characteristics used in linear regression models (entire study cohort) 
 All  Male Female  
  CMV- 
(N = 60) 
CMV+ 
(N = 76) 
P CMV- 
(N = 36) 
CMV+ 
(N = 36) 
P CMV- 
(N = 24) 
CMV+ 
(N = 40) 
P 
cfPWV (m/s)  
median (IQR)  
9.2 (3.2) 9.4 (2.9) n.s. 9.0 (2.4) 10.1 (2.5) 0.022 9.7 (4.8) 8.9 (2.9) n.s. 
Age years  
mean ± STD  
69.2 ± 7.4 70.2 ± 7.1 n.s. 69.6 ± 7.6 70.7 ± 8.5 n.s. 68.5 ± 7.2 69.7 ± 5.5 n.s. 
SES  
median (IQR) 
4.3 (3.0) 5.5 (4.8) n.s. 4.1 (3.9) 6.0 (5.7) n.s. 5.5 (4.5) 4.7 (3.1) n.s. 
Smoking (pack-years) 
median (IQR) 
0.5 (10.1) 0.2 (7.0) n.s. 0.3 (12.5) 2.4 (22.0) n.s. 0.6 (9.4) 0.0 (3.2) n.s. 
WHR 
mean ± STD 
1.0 ± 0.2 0.9 ± 0.1 n.s. 1.0 ± 0.2 1.0 ± 0.1 n.s. 0.9 ± 0.1 0.9 ± 0.1 n.s. 
TC/HDL-C  
mean ± STD 
3.3 ± 1.0 3.2 ± 0.8 n.s. 3.6 ± 1.0 3.3 ± 0.8 n.s. 3.0 ± 0.9 3.1 ± 0.8 n.s. 
SBP lying (mmHg) 
median (IQR) 
140 (21) 136 (27) n.s. 141 (22) 135 (27) n.s. 136 (26) 130 (28) n.s. 
SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure 
aParameters for which median (IQR) is provided were log-transformed for use in linear regression models 
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Table 2. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately 
 Beta coefficient (95% Confidence Interval)a 
 Model 1b Model 2c Model 3d Model 4e 
CMV serostatus/all (N = 136) -0.018 (-0.019, 0.056) -0.011 (-0.022, 0.044) 0.014 (-0.020, 0.047) 0.021 (-0.008, 0.049)f 
Model split by sex 
CMV serostatus/men (N = 72) 0.046 (0.001, 0.092)* 0.048 (0.008, 0.087)* 0.055 (0.016, 0.094)** 0.059 (0.024, 0.093)g** 
CMV serostatus/women (N = 64) -0.016 (-0.078, 0.046) -0.027 (-0.081, 0.027) -0.024 (-0.079, 0.031) -0.010 (-0.055, 0.035)h 
alog10 units 
bModel 1 unadjusted model. 
cModel 2 adjusted for age, socioeconomic status, and sex (entire cohort only).  
dModel 3 additionally adjusted for smoking pack-years and WHR.  
eModel 4 additionally adjusted for lying SBP and total TC/HDL-C. 
fR-squared of fully adjusted model: 0.474 
gR-squared of fully adjusted model: 0.550 
hR-squared of fully adjusted model: 0.554 
*P < 0.05; **P < 0.01 
 
 
Table 3. Association between cytomegalovirus serostatus and CD4 Tmem population size among the entire sub-cohort and among men and 
women separately 
 Beta coefficient (95% Confidence Interval)a 
 Model 1b Model 2c Model 3d 
CMV serostatus/all (N = 123) 0.048 (0.004, 0.092)* 0.056 (0.013, 0.100)* 0.053 (-0.009, 0.097)* 
Model split by sex 
CMV serostatus/men (N = 66) 0.079 (0.027, 0.132)** 0.078 (0.024, 0.132)** 0.073 (0.18, 0.128)* 
CMV serostatus/women (N = 57) 0.032 (-0.040, 0.104) 0.034 (-0.039, 0.106) 0.028 (-0.046, 0.101) 
alog10 units 
bModel 1 unadjusted.  
cModel 2 adjusted for age, socioeconomic status, and sex (entire cohort only).  
dModel 3 additionally adjusted for smoking pack-years and WHR.  





Table 4. Association between CD4 Tmem and cfPWV among the entire sub-cohort and among CMV- and CMV+ participants separately 
 Beta coefficient (95% Confidence Interval)a 
 Model 1b Model 2c Model 3d Model 4e Model 5f 
CD4 Tmem /all (N = 123) 0.045 (-0.115, 0.205) -0.035 (-0.128, 0.199) 0.040 (-0.106, 0.187) 0.046 (-0.100, 0.193) 0.020 (-0.104, 0.144)g 
Models split by CMV serostatus:      
CD4 Tmem /CMV- (N = 51)   -0.289 (-0.561,-0.017)* -0.143 (-0.391, 0.105) -0.149 (-0.396, 0.099) -0.116 (-0.337, 0.104)h 
CD4 Tmem /CMV+ (N = 72)   0.249 (-0.057, 0.441)* 0.206 (0.018, 0.394)* 0.235(0.044, 0.425)* 0.181 (0.027, 0.335)i* 
alog10 units 
bModel 1 unadjusted.  
cModel 2 adjusted for CMV (unless stratified by CMV) 
dModel 3 additionally adjusted for age and socioeconomic status 
eModel 4 additionally adjusted for smoking pack-years and WHR.  
fModel 5 additionally adjusted for lying SBP and TC/HDL-C.  
gR-squared of fully adjusted model: 0.472 
hR-squared of fully adjusted model: 0.524 
iR-squared of fully adjusted model: 0.528 




Table 5: CMV protein-covering peptide-pools used for T-cell stimulationa 
Pool CMV Protein(s) No. of Peptides 
1 UL555 224 
2 UL83 138 
3 UL86 340 
4 UL122 120 
5 UL123 143 
6 UL153 67 
7 UL32 260 
8 UL28 92 
9 UL48Aa 281 
10 UL48Ba 281 
11 US3 44 
12 UL151& UL82 219 (82 &137) 
13 UL94 & US29 197 (84 &113) 
14 US24 & UL36 240 (123 &117) 
aA panel of 19 CMV protein-spanning peptide pools was previously shown to correlate highly with the CD4 and CD8 T-cell response against 203 tested CMV 
proteins.[35] The original panel contained UL99, UL103, and US32 in addition, which had been used previously but were left out here since 
responses were absent in >100 White British people. 





Materials and methods 
 
Participants and samples 
GPs were instructed to search their electronic patient records with respect to the study’s 
inclusion and exclusion criteria, compile a list of all potentially eligible participants, assign a 
number to each individual, and communicate the total number eligible to the PCRN.  
Over several recruitment waves the PCRN provided each practice with a list of random 
numbers. Larger practices were instructed to reach out to 100 individuals per wave and engaged 
in more waves than smaller practices, which were instructed to reach out to 50 individuals per 
wave. For each wave of invitations, new random numbers were sent to each practice (previously 
used numbers were excluded). Recruitment occurred in multiple waves over a total of 2.5 years.  
Practices mailed written invitations to all selected individuals. If interested, invited participants 
contacted the research nurse team at the Clinical Investigation and Research Unit (CIRU) of 
Brighton and Sussex University Hospital NHS Trust (BSUHT) to schedule an initial screening 
appointment, which took place in their GP’s practice. At this appointment, inclusion/exclusion 
criteria were double-checked, written informed consent was obtained from eligible participants, 
a blood sample was obtained by venepuncture for testing CMV-serostatus, and participants 
were invited to attend the main study appointment at CIRU.  
Participants from a previous study (N = 131) using the same random recruitment approach 3 
years earlier, were invited as well (direct mail-out by CIRU). Respondents (N = 30) were invited 
directly for the main appointment after confirming eligibility via telephone. Their CMV status 
had previously been recorded but was not a criterion for selection.  
At the main study appointment, eligibility of all participants was reviewed, a detailed medical 
history was obtained, vascular measurements were performed, and additional blood samples 
were taken for measuring blood counts, lipid values, and general blood biochemistry. 
Individuals were recruited in the order in which responses were received. Vascular laboratory 
staff were blinded to the CMV status of participants at all times. Recruitment was continued 
until N = 209 individuals had attended the main appointment. After reviewing eligibility 
according to the selection criteria N = 193 participants were eligible for assessment in the 




Briefly, with the patient in supine position the carotid and femoral arteries are located and the 
positions where carotid and femoral pressures are to be measured are marked. The distance 
between these points is measured and recorded in the analysis software. The sensors are 
positioned on the respective measurement points for data acquisition. During measurement, the 
time-delay between recording the pulse wave at the carotid and femoral arteries is recorded 
along with the changes in central and peripheral brachial blood pressure. The analysis software 
subsequently displays pulse wave velocity and the central (carotid) pressure waveform analysis. 
Measurement of cfPWV was attempted in 193 and completed in 181 individuals. In 12 
individuals the procedure was aborted due to compliance issues. A total of N = 137 (76%) of 
cfPWV measurements passed quality control (QC) by two physicians blinded to the CMV 
infection status of participants. QC was based on the shape of the recordings and the consistency 
(wave form) of the ten consecutive waves. Extreme outliers in terms of cfPWV (> LQ- (3*IQR); 
< (UQ+3*IQR) were removed during analysis leaving N = 136 accepted measurements for 
cfPWV. 
 
Whole blood antibody staining for T-cell phenotyping 
Fresh, sodium-heparin-anticoagulated whole blood (100 μL) was incubated with monoclonal, 
fluorescence-labeled staining antibodies as follows. Anti-CD45-AlexaFluor (AF)700, anti-
CD3-Pacific Blue (PB), anti-CD4-Brilliant Violet (BV)510, anti-CD8α-allophycocyanin 
(APC)-H7, anti-CCR7 BV605, anti-CD45RA-Fluorescein-iso-thio-cyanate (FITC) (all 
BioLegend, Cambridge, UK). Cells were incubated for 20 min at RT in the dark followed by 
addition of BD lysis buffer (BD) and incubation for 10 min according to the manufacturer’s 
instructions. Samples were then centrifuged (5 min at 350g), resuspended in PBS and spun 
again (5 min at 350g). Finally, cells were fixed (1% paraformaldehyde in water) and washed. 




Twenty-five μg per peptide per pool (PepMixTM, JPT Peptide Technologies, Berlin, Germany) 
were dissolved in 100 μL of DMSO (Sigma-Aldrich, Gillingham, UK) (0.25 μg/μL). For T-cell 
stimulation assays 2 μL of the 0.25 μg/μL CMV-peptide solutions were used for a final 
concentration of 1 μg/mL per peptide. All assays included a positive control that consisted of 1 
μg/ml (final concentration) of Staphylococcal enterotoxin B from Staphylococcus aureus (SEB, 
 3 
Sigma) dissolved in DMSO, and a negative control consisting of 2 μL of DMSO alone (i.e., the 
peptide solvent). A list of all CMV proteins used in the study is provided in Table 5.  
 
CMV-reactivity of T-cells 
CMV-specific T-cells from CMV+ individuals were activated by incubating PBMC for 16 h 
overnight (37 °C, humidified 5% CO2 atmosphere) with peptide pools, positive and negative 
controls. Per tube 1x106 PBMCs were incubated with 2 μL of the corresponding CMV peptide 
pool, 1 μL of SEB solution (positive control, final concentration 1 μg/mL) or 2 μL of DMSO 
(negative control) in complete RPMI media (final incubation volume 250 μL). After 2 h in a 
standard incubator (37°C, humidified 5% CO2 atmosphere) each tube received 250 μL of 
complete RPMI containing 10 μg/mL of Brefeldin A (BFA), resulting in a final volume of 500 
μL for the remaining incubation time (14 h). Thereafter each tube was incubated for 10 min at 
37 °C (water bath) with 100 μL of 20 mM EDTA (Sigma). Subsequently, samples were washed 
with 3 mL of wash buffer (PBS with 0.5% w/v BSA and 0.1% w/v sodium azide, (Sigma) and 
centrifuged at 400g for 8 min at RT (‘wash step’). Samples were then surface-stained (30 min 
at 4 °C in the dark) with fluorochrome conjugated monoclonal antibodies including anti-CD3 
Pacific Blue, anti-CD4 BV510, anti-CD8a PE-Cy7, anti-CCR7 BV605, and anti-CD45RA 
PerCP/Cy5.5 (all Biolegend), followed by a wash step. Following the surface stain 1ml of 1x 
BD ‘FACS Lysing Solution’ (BD) was added to each tube and tubes incubated for 10 min in 
the dark. Another wash step followed and subsequently, BD ‘Permeabilization solution 2’ was 
added to each tube and samples were incubated for 10 min in the dark. After a further wash 
step, cells were stained intracellularly with anti-IL-2 APC, anti-TNFα AF 700 and anti-IFN-γ 
FITC (all Biolegend) for 30 min at 4 °C in the dark followed by a wash step. Then, 1 mL of 
0.5% paraformaldehyde (in water) was added to each tube and incubated in the dark for 5 min. 
After a final wash step cells were stored at 4 °C in the dark until acquisition.  
 
Data acquisition and analysis 
Samples were acquired on an LSR II flow-cytometer (BD). FlowJo v9.x software (Tree Star 
Inc., Ashland, OR) was used for data analysis. Gating strategy is described in Figure S6. 
 
Quality control for flow-cytometry 
Comparable day-to-day performance of the LSR II flow-cytometer was ascertained by running 
CS&T calibration beads (BD) on a daily basis. In addition, 8-peak Rainbow beads were used 
prior to every run in order to adjust PMTs in such a way that with respect to each detector, 
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Linear regression models were adjusted for covariates as follows.  
(1) Linear regression models testing an association of CMV infection status (CMV+ or CMV-
) with cfPWV. First, models were unadjusted. They were then adjusted for sex (total sample 
only), age, and SES. Next, they were adjusted smoking pack-years and WHR. Finally, models 
were adjusted for SBP and TC/HDL-C.  
(2) Linear regression models testing an association of CMV infection status with Tmem. Initial 
models were unadjusted. Subsequent models were adjusted for age, SES, and sex (unless 
stratified by sex). They were then adjusted for smoking pack-years and WHR. Models were not 
adjusted for SBP and TC/HDL-C as no consistent effect of these parameters on Tmem is known.  
(3) Linear regression models testing an association of Tmem with cfPWV. Initial models were 
unadjusted. Subsequent models were adjusted for CMV (unless stratified by CMV), and then 
age (unless stratified by age) and SES. Finally, models were adjusted for WHR and smoking 
pack-years. Finally, models were adjusted for SBP and TC/HDL-C. To avoid collinearity, these 
models were not adjusted for sex, because the effect of sex was already accounted for by the 
proportions of Tmem (which were higher in men than in women). 
 
Data trends in scatter plots were visualised using the SPSS ‘fit line’ command (linear model). 
Bivariate correlations were tested using the ‘correlate’ command in SPSS, the Pearson 












responses recorded by CIRU (N=245)
patients seen at vascular lab appointment (N=209)
PWV mesasurement attempted (N=193)
PWV measurements completed (N=181)
not eligible at screening (N=15)
declined before or after 
screening visit (N=8)
no longer needed (N=13)
not eligible on review (N=16)
measurements incomplete (N=12)
valid PWV measurements (analytic samples)
for cfPWV (N=137)






Figure S2. cfPWV is higher in CMV+ compared with CMV- older men. Diagrams show the 
distribution of cfPWV in men and women stratified by CMV infection status. Box plots show 
median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers 



























Figure S3. Gating strategy for whole blood surface phenotyping. Lymphocytes were gated in 
an SSC/FSC plot. Singlets were gated in an FSC-A/FSC-H plot, doublets were excluded. 
From the singlet gate a CD3 T-cell gate was created in a CD3/CD8 fluorescence dot-plot (top 
right). A CD4 versus CD8 fluorescence dot plot allowed to visualize T-cell subsets based on 
CD4 and CD8 expression (middle). For the analysis of CCR7 and CD45RA expression CD4 
T-cells (bottom left) and CD8 T-cells (bottom right) were gated separately. The canonical 
naïve (CCR7+CD45RA+, TNA), central memory (CCR7+CD45RA-, TCM), effector memory 
(CCR7-CD45RA-, TEM), and revertant memory T-cell subsets (CCR7-CD45RA+, TEMRA) 
were identified as shown. The same gating sequence and strategy was applied to all samples. 
The expression of CD28 was used to aid the discrimination between the subsets in that the 
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Figure S4. Differential distribution of canonical CD4 and CD8 memory T-cell subsets in 
men and women stratified by CMV status. A. Box plots show the distribution of CD4 TNA, 
TCM, TEM, and TEMRA subsets in men and women among the entire cohort (top), CMV- 
individuals (middle) and CMV+ individuals (bottom). B. Box plots show the distribution of 
the corresponding CD8 T cell subsets in each group. Box plots show median and interquartile 
range, outlier limits (whiskers, LQ-1.5*IQR, UQ + 1.5*IQR), outliers (o) and extreme values 























































































Figure S5: Bar charts showing the distribution of CD4 (top) and CD8 (bottom) T-cell 
responsiveness to 16 different CMV proteins arranged in 14 stimulation pools. Each column 
represents the number of positive responses among CMV+ people to one stimulation pool. 
Positive responses were identified by intracellular cytokine staining following stimulation of 









































































Figure S6. Gating strategy for ICS on antigen-stimulated, fresh PBMC. (1) Lymphocytes 
were gated in an SSC/FSC plot. (2) Singlets were gated in an FSC-A/FSC-H plot, and 
doublets were excluded. (3) From the singlet gate, two CD3 T-cell gates were created, one in 
a CD3/CD4 fluorescence dot-plot (top right) and one in a CD3/CD8 fluorescence dot-plot. 
Each gate allowed for inclusion of sometimes strongly TCR downregulated T-cells. (4) The 
two CD3 gates were then combined in a Boolean gate (OR) for gating CD4 and CD8 T-cells 
in a CD4 versus CD8 fluorescence dot plot, which allowed to visualize T-cell subsets based 
on CD4 and CD8 expression. (5) For the analysis of activated T-cells, CD4 and CD8 T-cells 
were plotted versus the activation markers (IL-2, TNF, and IFN-g). These gates were overlaid 
with the canonical memory T-cell subsets defined by CCR7 and CD45RA expression. The 
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Table S1. Association between cytomegalovirus serostatus and cfPWV among men and women 
separately, fully adjusted model 
 Beta coefficient (95% Confidence Interval)a P value 
Menb   
CMV serostatus 0.059 (0.024, 0.093) 0.001 
Age 0.005 (0.003, 0.008) 0.000 
SES -0.087 (-0.163, -0.012) 0.024 
WHR 0.142 (0.017, 0.267) 0.027 
Smoking pack-years 0.000 (-0.006, -0.006) 0.961 
TC/HDL-C -0.006 (-0.026, 0.014) 0.562 
SBP lying 0.732 (0.422, 1.041) 0.001 
Womenc   
CMV serostatus -0.010 (-0.055, 0.035) 0.661 
Age 0.007 (0.003, 0.011) 0.001 
SES 0.064 (-0.037, 0.165) 0.212 
WHR -0.219 (-0.556, 0.118) 0.198 
Smoking pack-years 0.007 (0.000, 0.015) 0.060 
TC/HDL-C -0.004 (-0.024, 0.032) 0.776 
SBP lying 1.000 (0.641, 1.359) 0.000 
SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, 
SBP:systolic blood pressure 
alog10 units 
bR-squared of fully adjusted model: 0.550 




Table S2. Additional information on smoking and blood pressure (entire cohort) 
 All  Male  Female  
  
CMV- 
(N = 60) 
CMV+ 
(N = 76) 
P 
CMV- 
(N = 36) 
CMV+ 
(N = 36) 
P 
CMV- 
(N = 24) 
CMV+ 
(N = 40) 
P 
DBP lying (mmHg) 
median (IQR) 
76.8 (11.1) 74.5 (14.5) n.s. 79.8 (9.1) 76.0 (19.3) n.s. 73.8 (9.6) 73.8 (14.1) n.s. 
PP lying (mmHg) 
median (IQR) 
58.0 (18.9) 57.2 (18.1) n.s. 57.5 (16.0) 58.0 (15.4) n.s. 61.8 (19.5) 55.0 (23.1) n.s. 
Ever smoker N (% in column) 32 (53.3) 43 (57.6) n.s. 19 (52.8) 23 (63.9) n.s. 13 (54.2) 20 (50.0) n.s. 
Current smoker N (% in column) 6 (10.0) 5 (6.5) n.s. 5 (13.8) 3 (8.3) n.s. 1 (4.1) 2 (5.0) n.s. 
Time since smoking cessation in ex-
smokers, mean ± STD 
31.7 ± 14.2 34.1 ± 13.2 n.s. 29.6 ± 14.5 31.0 ± 14.2 n.s. 34.0 ± 14.0 37.5 ± 11.5 n.s. 




Table S3. Common medicationsa,b (entire cohort)  
 All  Male  Female  
  
CMV- 
(N = 60) 
CMV+ 
(N = 76) 
P 
CMV- 
(N = 36) 
CMV+ 
(N = 36) 
P 
CMV- 
(N = 24) 
CMV+ 
(N = 40) 
P 
Cholesterol lowering drugs 
(all) 
17 (28.3) 14 (18.4) n.s. 14 (38.9) 8 (22.2) n.s. 3 (12.5) 6 (15.0) n.s. 
Statin 16 (26.7) 14 (18.4) n.s. 13 (36.1) 8 (22.2) n.s. 3 (12.5) 6 (15.0) n.s. 
Oral anti-hyperglycemic 3 (5.0) 0 (0.0) n.s. 1 (2.8) 0 (0.0) n.s. 2 (8.3) 0 (0.0) n.s. 
Blood pressure lowering 
drugs (any) 
18 (30) 22 (28.9) n.s. 11 (30.6) 9 (25.0) n.s. 7 (29.2) 13 (32.5) n.s. 
Blood pressure lowering 
drugs (number) 
mean± STD 
0.43 ± 0.77 0.49 ± 0.92 n.s. 0.44± 0.77 0.47± 0.97 n.s. 0.42± 0.77 0.50± 0.87 n.s. 
Diuretic 3 (5.0) 8 (10.5) n.s. 1 (2.8) 3 (8.3) n.s. 2 (8.3) 5 (12.5) n.s. 
Beta-blocker 8 (13.3) 5 (6.6) n.s. 5 (13.9) 2 (5.6) n.s. 3 (12.5) 3 (7.5) n.s. 
Ca-antagonist 6 (10.0) 5 (6.6) n.s. 4 (11.1) 3 (8.3) n.s. 2 (8.3) 2 (5.0) n.s. 
ACE inhibitor/AT-II 
receptor antagonist 
12 (20) 16 (21.1) n.s. 8 (22.2) 7 (19.4) n.s. 4 (16.7) 9 (22.5) n.s. 
Centrally acting anti-
hypertensive 
0 (0.0) 1 (1.3) n.s. 0 (0.0) 1 (2.8) n.s. 0 (0.0) 0 (0.0) n.s. 
Nitroglycerine 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 0 (0) 0 (0.0) n.s. 
Platelet aggregation 
inhibitor 
6 (10.0) 9 (11.8) n.s. 5 (13.9) 7 (19.4) n.s. 1 (4.2) 2 (5.0) n.s. 
aMedications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, 
osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers. 




Table S4. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately 
 Beta coefficient (95% Confidence Interval)a 
 Model 4Ab Model 4Bc 
CMV serostatus/all (N = 136) 0.021 (-0.008, 0.049) 0.022 (-0.006, 0.050) 
Models split by gender:   
CMV serostatus/men (N = 72) 0.059 (0.024, 0.093)** 0.059 (0.024, 0.094)** 
CMV serostatus/women (N = 64) -0.011 (-0.056, 0.035) -0.011 (-0.056, 0.033) 
alog10 units 
bModel 4A corresponds to Model 4 in Table 2, additionally adjusted for the number of anti-hypertensive medications taken. 
cModel 4B corresponds to Model 4 in Table 2, additionally adjusted for presence/absence of antihypertensive medication (yes/no) 




Table S5. Characteristics used in linear regression models (sub-cohort with T-cell phenotyping data)a 
 All  Male  Female  
 
CMV- 
(N = 51) 
CMV+ 
(N = 72) 
P 
CMV- 
(N = 32) 
CMV+ 
(N = 34) 
P 
CMV- 
(N = 19) 
CMV+ 
(N = 38) 
P 
PWV (m/s)  
median (IQR)  
9.5 (3.4) 9.4 (3.0) n.s. 8.9 (2.9) 10.1 (2.5) 0.029 9.8 (4.3) 8.9 (3.3) n.s. 
Age years  
mean ± STD 
69.1 ± 7.4 70.4 ± 7.2 n.s. 69.7 ± 7.8 71.0 ± 8.7 n.s. 68.1 ± 6.8 69.8 ± 5.6 n.s. 
SES  
median (IQR) 
4.3 (3.9) 6.0 (4.8) n.s. 4.2 (3.9) 6.0(5.2) n.s. 5.0 (3.0) 4.7 (3.1) n.s. 
Smoking (pack-years) 
median (IQR) 
0.5 (13.0) 0.1 (6.8) n.s. 1.3 (12.5) 1.1 (23.1) n.s. 0.5 (15.0) 0.0 (3.2) n.s. 
WHR 
mean ± STD 
1.0 ± 0.2 0.9 ± 0.1 n.s. 1.0 ± 0.20 1.0 ± 0.1 n.s. 0.9 ± 0.0 0.9± 0.1 n.s. 
TC/HDL-C 
mean ± STD 
3.4 ± 0.9 3.2 ± 0.8 n.s. 3.5 ± 0.9 3.3 ± 0.8 n.s. 3.1 ± 1.0 3.0 ± 0.8 n.s. 
SBP lying (mmHg) 
median (IQR) 
142 (18) 135 (26) n.s 141 (16) 137 (24) n.s 142 (25) 131 (28) n.s 
SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure 
aParameters for which median (IQR) is provided were log-transformed for use in linear regression models 
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Table S6. Additional information on smoking and blood pressure (sub-cohort with T-cell phenotyping data) 

















DBP lying (mmHg) 
median (IQR) 
77.5 (10.0) 74.8 (14.8) n.s 80.3 (9.0) 77.0 (20.1) n.s. 74.5 (10.0) 73.8 (14.1) n.s. 
PP lying (mmHg) 
median (IQR) 
58.5 (18.5) 57.3 (18.1) n.s. 57.5 (12.9) 58.8 (14.4) n.s. 68.5 (21.5) 54.0 (23.1) n.s. 
Ever smoker N (% in column) 28 (55.0) 39 (54.1) n.s. 18 (56.2) 21 (61.8) n.s. 10 (52.3) 18 (47.3) n.s. 
Current smoker N (% in column) 5 (9.8) 4 (5.6) n.s. 4 (12.5) 2 (5.9) n.s. 1 (5.3) 2 (5.3) n.s. 
Time since smoking cessation in ex-
smokers, mean ± STD 
30.8 ± 14.9  33.9 ± 13.8 n.s. 29.6 ± 14.5 30.8 ± 14.5 n.s. 32.7 ± 16.1 37.7 ± 12.2 n.s. 




Table S7. Common medicationsa,b (sub-cohort with T-cell phenotyping data)  
 All  Male  Female  
 
CMV- 
(N = 51) 
CMV+ 
(N = 72) 
P 
CMV- 
(N = 32) 
CMV+ 
(N = 34) 
P 
CMV- 
(N = 19) 
CMV+ 
(N = 38) 
P 
Cholesterol lowering drugs (all) 15 (29.4) 14 (19.4) n.s. 12 (37.5) 8 (23.5) n.s. 3 (15.8) 6 (15.8) n.s. 
Statin 14 (27.5) 14 (19.4) n.s. 11 (34.4) 8 (23.5) n.s. 3 (15.8) 6 (15.8) n.s. 
Oral anti-hyperglycemic 3 (5.9) 0 (0.0) n.s. 1 (3.1) 0 (0.0) n.s. 2 (10.5) 0 (0.0) n.s. 
Blood pressure lowering drugs (any) 16 (31.4) 21 (29.2) n.s. 10 (31.3) 9 (26.5) n.s. 6 (31.6) 12 (31.6) n.s. 
BP medications (No) 
mean± STD 
0.41 ± 0.70 0.49 ± 0.91 n.s. 0.44 ± 0.75 0.50 ± 0.99 n.s. 0.37 ± 0.59 0.47 ± 0.86 n.s. 
Diuretic 2 (3.9) 7 (9.7) n.s. 1 (3.1) 3 (8.8) n.s. 1 (5.3) 4 (10.5) n.s. 
Beta-blocker 6 (11.8) 5 (6.9) n.s. 4 (12.5) 2 (5.9) n.s. 2 (10.5) 3 (7.9) n.s. 
Ca-antagonist 6 (11.8) 5 (6.9) n.s. 4 (12.5) 3 (8.8) n.s. 2 (10.5) 2 (5.3) n.s. 
ACE inhibitor/AT-II receptor antagonist 10 (19.6) 15 (20.8) n.s. 7 (22.2) 7 (21.9) n.s. 3 (15.8) 8 (21.1) n.s. 
Centrally acting anti-hypertensive 0 (0.0) 1 (1.4) n.s. 0 (0.0) 1 (2.9) n.s. 0 (0.0) 0 (0.0) n.s. 
Nitroglycerine 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 
Platelet aggregation inhibitor 4 (7.8) 9 (12.5) n.s. 3 (9.4) 7 (20.6) n.s. 1 (5.3) 2 (5.3) n.s. 
aMedications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, 
osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers. 





Table S8. Association between cytomegalovirus seropositivity and CD8 Tmem population size among the entire sub-cohort with phenotyping 
data and among men and women separately 
Sample Beta coefficient (95% Confidence Interval)a 
 Model 1b Model 2c Model 3d 
CMV serostatus/all (N = 123) 0.058 (0.029, 0.086)*** 0.063 (0.034, 0.092)*** 0.064 (0.034, 0.093)*** 
Models split by gender: 
CMV serostatus/men (N = 66) 0.059 (0.025, 0.092)** 0.059 (0.025, 0.093)** 0.060 (0.025, 0.094)** 
CMV serostatus/women (N = 57) 0.070 (0.020, 0.119)** 0.072 (0.022, 0.123)** 0.073 (0.021, 0.125)** 
alog10 units 
bModel 1 unadjusted.  
cModel 2 adjusted for age, socioeconomic status, and sex (total sample only).  
dModel 3 additionally adjusted for smoking pack-years and waist-to-hip ratio.  






Materials and methods 
 
Participants and samples 
GPs were instructed to search their electronic patient records with respect to the study’s 
inclusion and exclusion criteria, compile a list of all potentially eligible participants, assign a 
number to each individual, and communicate the total number eligible to the PCRN.  
Over several recruitment waves the PCRN provided each practice with a list of random 
numbers. Larger practices were instructed to reach out to 100 individuals per wave and engaged 
in more waves than smaller practices, which were instructed to reach out to 50 individuals per 
wave. For each wave of invitations, new random numbers were sent to each practice (previously 
used numbers were excluded). Recruitment occurred in multiple waves over a total of 2.5 years.  
Practices mailed written invitations to all selected individuals. If interested, invited participants 
contacted the research nurse team at the Clinical Investigation and Research Unit (CIRU) of 
Brighton and Sussex University Hospital NHS Trust (BSUHT) to schedule an initial screening 
appointment, which took place in their GP’s practice. At this appointment, inclusion/exclusion 
criteria were double-checked, written informed consent was obtained from eligible participants, 
a blood sample was obtained by venepuncture for testing CMV-serostatus, and participants 
were invited to attend the main study appointment at CIRU.  
Participants from a previous study (N = 131) using the same random recruitment approach 3 
years earlier, were invited as well (direct mail-out by CIRU). Respondents (N = 30) were invited 
directly for the main appointment after confirming eligibility via telephone. Their CMV status 
had previously been recorded but was not a criterion for selection.  
At the main study appointment, eligibility of all participants was reviewed, a detailed medical 
history was obtained, vascular measurements were performed, and additional blood samples 
were taken for measuring blood counts, lipid values, and general blood biochemistry. 
Individuals were recruited in the order in which responses were received. Vascular laboratory 
staff were blinded to the CMV status of participants at all times. Recruitment was continued 
until N = 209 individuals had attended the main appointment. After reviewing eligibility 
according to the selection criteria N = 193 participants were eligible for assessment in the 




Briefly, with the patient in supine position the carotid and femoral arteries are located and the 
positions where carotid and femoral pressures are to be measured are marked. The distance 
between these points is measured and recorded in the analysis software. The sensors are 
positioned on the respective measurement points for data acquisition. During measurement, the 
time-delay between recording the pulse wave at the carotid and femoral arteries is recorded 
along with the changes in central and peripheral brachial blood pressure. The analysis software 
subsequently displays pulse wave velocity and the central (carotid) pressure waveform analysis. 
Measurement of cfPWV was attempted in 193 and completed in 181 individuals. In 12 
individuals the procedure was aborted due to compliance issues. A total of N = 137 (76%) of 
cfPWV measurements passed quality control (QC) by two physicians blinded to the CMV 
infection status of participants. QC was based on the shape of the recordings and the consistency 
(wave form) of the ten consecutive waves. Extreme outliers in terms of cfPWV (> LQ- (3*IQR); 
< (UQ+3*IQR) were removed during analysis leaving N = 136 accepted measurements for 
cfPWV. 
 
Whole blood antibody staining for T-cell phenotyping 
Fresh, sodium-heparin-anticoagulated whole blood (100 μL) was incubated with monoclonal, 
fluorescence-labeled staining antibodies as follows. Anti-CD45-AlexaFluor (AF)700, anti-
CD3-Pacific Blue (PB), anti-CD4-Brilliant Violet (BV)510, anti-CD8α-allophycocyanin 
(APC)-H7, anti-CCR7 BV605, anti-CD45RA-Fluorescein-iso-thio-cyanate (FITC) (all 
BioLegend, Cambridge, UK). Cells were incubated for 20 min at RT in the dark followed by 
addition of BD lysis buffer (BD) and incubation for 10 min according to the manufacturer’s 
instructions. Samples were then centrifuged (5 min at 350g), resuspended in PBS and spun 
again (5 min at 350g). Finally, cells were fixed (1% paraformaldehyde in water) and washed. 




Twenty-five μg per peptide per pool (PepMixTM, JPT Peptide Technologies, Berlin, Germany) 
were dissolved in 100 μL of DMSO (Sigma-Aldrich, Gillingham, UK) (0.25 μg/μL). For T-cell 
stimulation assays 2 μL of the 0.25 μg/μL CMV-peptide solutions were used for a final 
concentration of 1 μg/mL per peptide. All assays included a positive control that consisted of 1 
μg/ml (final concentration) of Staphylococcal enterotoxin B from Staphylococcus aureus (SEB, 
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Sigma) dissolved in DMSO, and a negative control consisting of 2 μL of DMSO alone (i.e., the 
peptide solvent). A list of all CMV proteins used in the study is provided in Table 5.  
 
CMV-reactivity of T-cells 
CMV-specific T-cells from CMV+ individuals were activated by incubating PBMC for 16 h 
overnight (37 °C, humidified 5% CO2 atmosphere) with peptide pools, positive and negative 
controls. Per tube 1x106 PBMCs were incubated with 2 μL of the corresponding CMV peptide 
pool, 1 μL of SEB solution (positive control, final concentration 1 μg/mL) or 2 μL of DMSO 
(negative control) in complete RPMI media (final incubation volume 250 μL). After 2 h in a 
standard incubator (37°C, humidified 5% CO2 atmosphere) each tube received 250 μL of 
complete RPMI containing 10 μg/mL of Brefeldin A (BFA), resulting in a final volume of 500 
μL for the remaining incubation time (14 h). Thereafter each tube was incubated for 10 min at 
37 °C (water bath) with 100 μL of 20 mM EDTA (Sigma). Subsequently, samples were washed 
with 3 mL of wash buffer (PBS with 0.5% w/v BSA and 0.1% w/v sodium azide, (Sigma) and 
centrifuged at 400g for 8 min at RT (‘wash step’). Samples were then surface-stained (30 min 
at 4 °C in the dark) with fluorochrome conjugated monoclonal antibodies including anti-CD3 
Pacific Blue, anti-CD4 BV510, anti-CD8a PE-Cy7, anti-CCR7 BV605, and anti-CD45RA 
PerCP/Cy5.5 (all Biolegend), followed by a wash step. Following the surface stain 1ml of 1x 
BD ‘FACS Lysing Solution’ (BD) was added to each tube and tubes incubated for 10 min in 
the dark. Another wash step followed and subsequently, BD ‘Permeabilization solution 2’ was 
added to each tube and samples were incubated for 10 min in the dark. After a further wash 
step, cells were stained intracellularly with anti-IL-2 APC, anti-TNFα AF 700 and anti-IFN-γ 
FITC (all Biolegend) for 30 min at 4 °C in the dark followed by a wash step. Then, 1 mL of 
0.5% paraformaldehyde (in water) was added to each tube and incubated in the dark for 5 min. 
After a final wash step cells were stored at 4 °C in the dark until acquisition.  
 
Data acquisition and analysis 
Samples were acquired on an LSR II flow-cytometer (BD). FlowJo v9.x software (Tree Star 
Inc., Ashland, OR) was used for data analysis. The gating strategies for phenotype staining of 
whole blood samples and intracellular cytokine staining for PBMC samples are described in 
Figures S3 and S6, respectively. 
 
Quality control for flow-cytometry 
Comparable day-to-day performance of the LSR II flow-cytometer was ascertained by running 
 4 
CS&T calibration beads (BD) on a daily basis. In addition, 8-peak Rainbow beads were used 
prior to every run in order to adjust PMTs in such a way that with respect to each detector, 




Linear regression models were adjusted for covariates as follows.  
(1) Linear regression models testing an association of CMV infection status (CMV+ or CMV-
) with cfPWV. First, models were unadjusted. They were then adjusted for sex (total sample 
only), age, and SES. Next, they were adjusted smoking pack-years and WHR. Finally, models 
were adjusted for SBP and TC/HDL-C.  
(2) Linear regression models testing an association of CMV infection status with Tmem. Initial 
models were unadjusted. Subsequent models were adjusted for age, SES, and sex (unless 
stratified by sex). They were then adjusted for smoking pack-years and WHR. Models were not 
adjusted for SBP and TC/HDL-C as no consistent effect of these parameters on Tmem is known.  
(3) Linear regression models testing an association of Tmem with cfPWV. Initial models were 
unadjusted. Subsequent models were adjusted for CMV (unless stratified by CMV), and then 
age (unless stratified by age) and SES. Finally, models were adjusted for WHR and smoking 
pack-years. Finally, models were adjusted for SBP and TC/HDL-C. To avoid collinearity, these 
models were not adjusted for sex, because the effect of sex was already accounted for by the 
proportions of Tmem (which were higher in men than in women). 
 
Data trends in scatter plots were visualised using the SPSS ‘fit line’ command (linear model). 
Bivariate correlations were tested using the ‘correlate’ command in SPSS, the Pearson 












responses recorded by CIRU (N=245)
patients seen at vascular lab appointment (N=209)
PWV mesasurement attempted (N=193)
PWV measurements completed (N=181)
not eligible at screening (N=15)
declined before or after 
screening visit (N=8)
no longer needed (N=13)
not eligible on review (N=16)
measurements incomplete (N=12)
valid PWV measurements (analytic samples)
for cfPWV (N=137)






Figure S2. cfPWV is higher in CMV+ compared with CMV- older men. Diagrams show the 
distribution of cfPWV in men and women stratified by CMV infection status. Box plots show 
median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers 



























Figure S3. Gating strategy for whole blood surface phenotyping. Lymphocytes were gated in 
an SSC/FSC plot. Singlets were gated in an FSC-A/FSC-H plot, doublets were excluded. 
From the singlet gate a CD3 T-cell gate was created in a CD3/CD8 fluorescence dot-plot (top 
right). A CD4 versus CD8 fluorescence dot plot allowed to visualize T-cell subsets based on 
CD4 and CD8 expression (middle). For the analysis of CCR7 and CD45RA expression CD4 
T-cells (bottom left) and CD8 T-cells (bottom right) were gated separately. The canonical 
naïve (CCR7+CD45RA+, TNA), central memory (CCR7+CD45RA-, TCM), effector memory 
(CCR7-CD45RA-, TEM), and revertant memory T-cell subsets (CCR7-CD45RA+, TEMRA) 
were identified as shown. The same gating sequence and strategy was applied to all samples. 
The expression of CD28 was used to aid the discrimination between the subsets in that the 
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Figure S4. Differential distribution of canonical CD4 and CD8 memory T-cell subsets in 
men and women stratified by CMV status. A. Box plots show the distribution of CD4 TNA, 
TCM, TEM, and TEMRA subsets in men and women among the entire cohort (top), CMV- 
individuals (middle) and CMV+ individuals (bottom). B. Box plots show the distribution of 
the corresponding CD8 T cell subsets in each group. Box plots show median and interquartile 
range, outlier limits (whiskers, LQ-1.5*IQR, UQ + 1.5*IQR), outliers (o) and extreme values 























































































Figure S5: Bar charts showing the distribution of CD4 (top) and CD8 (bottom) T-cell 
responsiveness to 16 different CMV proteins arranged in 14 stimulation pools. Each column 
represents the number of positive responses among CMV+ people to one stimulation pool. 
Positive responses were identified by intracellular cytokine staining following stimulation of 









































































Figure S6. Gating strategy for ICS on antigen-stimulated, fresh PBMC. (1) Lymphocytes 
were gated in an SSC/FSC plot. (2) Singlets were gated in an FSC-A/FSC-H plot, and 
doublets were excluded. (3) From the singlet gate, two CD3 T-cell gates were created, one in 
a CD3/CD4 fluorescence dot-plot (top right) and one in a CD3/CD8 fluorescence dot-plot. 
Each gate allowed for inclusion of sometimes strongly TCR downregulated T-cells. (4) The 
two CD3 gates were then combined in a Boolean gate (OR) for gating CD4 and CD8 T-cells 
in a CD4 versus CD8 fluorescence dot plot, which allowed to visualize T-cell subsets based 
on CD4 and CD8 expression. (5) For the analysis of activated T-cells, CD4 and CD8 T-cells 
were plotted versus the activation markers (IL-2, TNF, and IFN-g). These gates were overlaid 
with the canonical memory T-cell subsets defined by CCR7 and CD45RA expression. The 
































(2) singlet gate(1) lymphocyte gate (3) T-cell gates
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Table S1. Association between cytomegalovirus serostatus and cfPWV among men and women 
separately, fully adjusted model 
 Beta coefficient (95% Confidence Interval)a P value 
Menb   
CMV serostatus 0.059 (0.024, 0.093) 0.001 
Age 0.005 (0.003, 0.008) 0.000 
SES -0.087 (-0.163, -0.012) 0.024 
WHR 0.142 (0.017, 0.267) 0.027 
Smoking pack-years 0.000 (-0.006, -0.006) 0.961 
TC/HDL-C -0.006 (-0.026, 0.014) 0.562 
SBP lying 0.732 (0.422, 1.041) 0.001 
Womenc   
CMV serostatus -0.010 (-0.055, 0.035) 0.661 
Age 0.007 (0.003, 0.011) 0.001 
SES 0.064 (-0.037, 0.165) 0.212 
WHR -0.219 (-0.556, 0.118) 0.198 
Smoking pack-years 0.007 (0.000, 0.015) 0.060 
TC/HDL-C -0.004 (-0.024, 0.032) 0.776 
SBP lying 1.000 (0.641, 1.359) 0.000 
SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, 
SBP:systolic blood pressure 
alog10 units 
bR-squared of fully adjusted model: 0.550 




Table S2. Additional information on smoking and blood pressure (entire cohort) 
 All  Male  Female  
  
CMV- 
(N = 60) 
CMV+ 
(N = 76) 
P 
CMV- 
(N = 36) 
CMV+ 
(N = 36) 
P 
CMV- 
(N = 24) 
CMV+ 
(N = 40) 
P 
DBP lying (mmHg) 
median (IQR) 
76.8 (11.1) 74.5 (14.5) n.s. 79.8 (9.1) 76.0 (19.3) n.s. 73.8 (9.6) 73.8 (14.1) n.s. 
PP lying (mmHg) 
median (IQR) 
58.0 (18.9) 57.2 (18.1) n.s. 57.5 (16.0) 58.0 (15.4) n.s. 61.8 (19.5) 55.0 (23.1) n.s. 
Ever smoker N (% in column) 32 (53.3) 43 (57.6) n.s. 19 (52.8) 23 (63.9) n.s. 13 (54.2) 20 (50.0) n.s. 
Current smoker N (% in column) 6 (10.0) 5 (6.5) n.s. 5 (13.8) 3 (8.3) n.s. 1 (4.1) 2 (5.0) n.s. 
Time since smoking cessation in ex-
smokers, mean ± STD 
31.7 ± 14.2 34.1 ± 13.2 n.s. 29.6 ± 14.5 31.0 ± 14.2 n.s. 34.0 ± 14.0 37.5 ± 11.5 n.s. 




Table S3. Common medicationsa,b (entire cohort)  
 All  Male  Female  
  
CMV- 
(N = 60) 
CMV+ 
(N = 76) 
P 
CMV- 
(N = 36) 
CMV+ 
(N = 36) 
P 
CMV- 
(N = 24) 
CMV+ 
(N = 40) 
P 
Cholesterol lowering drugs 
(all) 
17 (28.3) 14 (18.4) n.s. 14 (38.9) 8 (22.2) n.s. 3 (12.5) 6 (15.0) n.s. 
Statin 16 (26.7) 14 (18.4) n.s. 13 (36.1) 8 (22.2) n.s. 3 (12.5) 6 (15.0) n.s. 
Oral anti-hyperglycemic 3 (5.0) 0 (0.0) n.s. 1 (2.8) 0 (0.0) n.s. 2 (8.3) 0 (0.0) n.s. 
Blood pressure lowering 
drugs (any) 
18 (30) 22 (28.9) n.s. 11 (30.6) 9 (25.0) n.s. 7 (29.2) 13 (32.5) n.s. 
Blood pressure lowering 
drugs (number) 
mean± STD 
0.43 ± 0.77 0.49 ± 0.92 n.s. 0.44± 0.77 0.47± 0.97 n.s. 0.42± 0.77 0.50± 0.87 n.s. 
Diuretic 3 (5.0) 8 (10.5) n.s. 1 (2.8) 3 (8.3) n.s. 2 (8.3) 5 (12.5) n.s. 
Beta-blocker 8 (13.3) 5 (6.6) n.s. 5 (13.9) 2 (5.6) n.s. 3 (12.5) 3 (7.5) n.s. 
Ca-antagonist 6 (10.0) 5 (6.6) n.s. 4 (11.1) 3 (8.3) n.s. 2 (8.3) 2 (5.0) n.s. 
ACE inhibitor/AT-II 
receptor antagonist 
12 (20) 16 (21.1) n.s. 8 (22.2) 7 (19.4) n.s. 4 (16.7) 9 (22.5) n.s. 
Centrally acting anti-
hypertensive 
0 (0.0) 1 (1.3) n.s. 0 (0.0) 1 (2.8) n.s. 0 (0.0) 0 (0.0) n.s. 
Nitroglycerine 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 0 (0) 0 (0.0) n.s. 
Platelet aggregation 
inhibitor 
6 (10.0) 9 (11.8) n.s. 5 (13.9) 7 (19.4) n.s. 1 (4.2) 2 (5.0) n.s. 
aMedications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, 
osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers. 




Table S4. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately 
 Beta coefficient (95% Confidence Interval)a 
 Model 4Ab Model 4Bc 
CMV serostatus/all (N = 136) 0.021 (-0.008, 0.049) 0.022 (-0.006, 0.050) 
Models split by gender:   
CMV serostatus/men (N = 72) 0.059 (0.024, 0.093)** 0.059 (0.024, 0.094)** 
CMV serostatus/women (N = 64) -0.011 (-0.056, 0.035) -0.011 (-0.056, 0.033) 
alog10 units 
bModel 4A corresponds to Model 4 in Table 2, additionally adjusted for the number of anti-hypertensive medications taken. 
cModel 4B corresponds to Model 4 in Table 2, additionally adjusted for presence/absence of antihypertensive medication (yes/no) 




Table S5. Characteristics used in linear regression models (sub-cohort with T-cell phenotyping data)a 
 All  Male  Female  
 
CMV- 
(N = 51) 
CMV+ 
(N = 72) 
P 
CMV- 
(N = 32) 
CMV+ 
(N = 34) 
P 
CMV- 
(N = 19) 
CMV+ 
(N = 38) 
P 
PWV (m/s)  
median (IQR)  
9.5 (3.4) 9.4 (3.0) n.s. 8.9 (2.9) 10.1 (2.5) 0.029 9.8 (4.3) 8.9 (3.3) n.s. 
Age years  
mean ± STD 
69.1 ± 7.4 70.4 ± 7.2 n.s. 69.7 ± 7.8 71.0 ± 8.7 n.s. 68.1 ± 6.8 69.8 ± 5.6 n.s. 
SES  
median (IQR) 
4.3 (3.9) 6.0 (4.8) n.s. 4.2 (3.9) 6.0(5.2) n.s. 5.0 (3.0) 4.7 (3.1) n.s. 
Smoking (pack-years) 
median (IQR) 
0.5 (13.0) 0.1 (6.8) n.s. 1.3 (12.5) 1.1 (23.1) n.s. 0.5 (15.0) 0.0 (3.2) n.s. 
WHR 
mean ± STD 
1.0 ± 0.2 0.9 ± 0.1 n.s. 1.0 ± 0.20 1.0 ± 0.1 n.s. 0.9 ± 0.0 0.9± 0.1 n.s. 
TC/HDL-C 
mean ± STD 
3.4 ± 0.9 3.2 ± 0.8 n.s. 3.5 ± 0.9 3.3 ± 0.8 n.s. 3.1 ± 1.0 3.0 ± 0.8 n.s. 
SBP lying (mmHg) 
median (IQR) 
142 (18) 135 (26) n.s 141 (16) 137 (24) n.s 142 (25) 131 (28) n.s 
SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure 
aParameters for which median (IQR) is provided were log-transformed for use in linear regression models 
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Table S6. Additional information on smoking and blood pressure (sub-cohort with T-cell phenotyping data) 

















DBP lying (mmHg) 
median (IQR) 
77.5 (10.0) 74.8 (14.8) n.s 80.3 (9.0) 77.0 (20.1) n.s. 74.5 (10.0) 73.8 (14.1) n.s. 
PP lying (mmHg) 
median (IQR) 
58.5 (18.5) 57.3 (18.1) n.s. 57.5 (12.9) 58.8 (14.4) n.s. 68.5 (21.5) 54.0 (23.1) n.s. 
Ever smoker N (% in column) 28 (55.0) 39 (54.1) n.s. 18 (56.2) 21 (61.8) n.s. 10 (52.3) 18 (47.3) n.s. 
Current smoker N (% in column) 5 (9.8) 4 (5.6) n.s. 4 (12.5) 2 (5.9) n.s. 1 (5.3) 2 (5.3) n.s. 
Time since smoking cessation in ex-
smokers, mean ± STD 
30.8 ± 14.9  33.9 ± 13.8 n.s. 29.6 ± 14.5 30.8 ± 14.5 n.s. 32.7 ± 16.1 37.7 ± 12.2 n.s. 




Table S7. Common medicationsa,b (sub-cohort with T-cell phenotyping data)  
 All  Male  Female  
 
CMV- 
(N = 51) 
CMV+ 
(N = 72) 
P 
CMV- 
(N = 32) 
CMV+ 
(N = 34) 
P 
CMV- 
(N = 19) 
CMV+ 
(N = 38) 
P 
Cholesterol lowering drugs (all) 15 (29.4) 14 (19.4) n.s. 12 (37.5) 8 (23.5) n.s. 3 (15.8) 6 (15.8) n.s. 
Statin 14 (27.5) 14 (19.4) n.s. 11 (34.4) 8 (23.5) n.s. 3 (15.8) 6 (15.8) n.s. 
Oral anti-hyperglycemic 3 (5.9) 0 (0.0) n.s. 1 (3.1) 0 (0.0) n.s. 2 (10.5) 0 (0.0) n.s. 
Blood pressure lowering drugs (any) 16 (31.4) 21 (29.2) n.s. 10 (31.3) 9 (26.5) n.s. 6 (31.6) 12 (31.6) n.s. 
BP medications (No) 
mean± STD 
0.41 ± 0.70 0.49 ± 0.91 n.s. 0.44 ± 0.75 0.50 ± 0.99 n.s. 0.37 ± 0.59 0.47 ± 0.86 n.s. 
Diuretic 2 (3.9) 7 (9.7) n.s. 1 (3.1) 3 (8.8) n.s. 1 (5.3) 4 (10.5) n.s. 
Beta-blocker 6 (11.8) 5 (6.9) n.s. 4 (12.5) 2 (5.9) n.s. 2 (10.5) 3 (7.9) n.s. 
Ca-antagonist 6 (11.8) 5 (6.9) n.s. 4 (12.5) 3 (8.8) n.s. 2 (10.5) 2 (5.3) n.s. 
ACE inhibitor/AT-II receptor antagonist 10 (19.6) 15 (20.8) n.s. 7 (22.2) 7 (21.9) n.s. 3 (15.8) 8 (21.1) n.s. 
Centrally acting anti-hypertensive 0 (0.0) 1 (1.4) n.s. 0 (0.0) 1 (2.9) n.s. 0 (0.0) 0 (0.0) n.s. 
Nitroglycerine 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 0 (0.0) 0 (0.0) n.s. 
Platelet aggregation inhibitor 4 (7.8) 9 (12.5) n.s. 3 (9.4) 7 (20.6) n.s. 1 (5.3) 2 (5.3) n.s. 
aMedications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, 
osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers. 





Table S8. Association between cytomegalovirus seropositivity and CD8 Tmem population size among the entire sub-cohort with phenotyping 
data and among men and women separately 
Sample Beta coefficient (95% Confidence Interval)a 
 Model 1b Model 2c Model 3d 
CMV serostatus/all (N = 123) 0.058 (0.029, 0.086)*** 0.063 (0.034, 0.092)*** 0.064 (0.034, 0.093)*** 
Models split by gender: 
CMV serostatus/men (N = 66) 0.059 (0.025, 0.092)** 0.059 (0.025, 0.093)** 0.060 (0.025, 0.094)** 
CMV serostatus/women (N = 57) 0.070 (0.020, 0.119)** 0.072 (0.022, 0.123)** 0.073 (0.021, 0.125)** 
alog10 units 
bModel 1 unadjusted.  
cModel 2 adjusted for age, socioeconomic status, and sex (total sample only).  
dModel 3 additionally adjusted for smoking pack-years and waist-to-hip ratio.  
*P < 0.05, **P < 0.01, ***P < 0.001 
 
 
